- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Renal cell carcinoma (RCC)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Avelumab – March 2020
Avelumab: Solution concentrate for I.V. infusion 200 mg in 10 ml; Bavencio®
Last updated
17 July 2020